Bayer AG will become the second-largest OTC drug firm and have a springboard to reach No. 1 by paying $14.2 billion for Merck & Co. Inc.’s consumer business, with plans to make the unit’s “very powerful household names in North America” popular worldwide, says Chairman Marijn Dekkers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?